FTC orders biggest ever divestiture in Teva Allergan deal

16-09-2016

FTC orders biggest ever divestiture in Teva Allergan deal

Photo: Courtesy of Teva

The US Federal Trade Commission (FTC) has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.


FTC, Teva, Allergan, divestiture,

More on this story

FTC hails M&A activity in ‘historic’ 2016
29-03-2017

LSIPR